Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2012.232 | A Multinational, Randomized, Double-Blind Study of Aflibercept Versus Placebo with Irinotecan/5-FU Combination (FOLFIRI) in Patients with Metastatic Colorectal Cancer (MCRC) after failure of an Oxaliplatinb Based Regimen | Dr MA Brigette Buig Yue |
| 2012.129 | A phase I open-label dose escalation study with expansion to assess the safety and tolerability of INC280 in patients with c-MET dependent advanced solid tumors | Prof. MA Brigette Buig Yue |
| 2013.294 | A phase Ib/II, open-label study of LJM716 in combination with BYL719 compared to taxane or irinotecan in patients with previously treated esophageal squamous cell carcinoma | Prof. MA Brigette Buig Yue |
| 2017.247 | Phase Ib study of PDR001 in combination with regorafenib in adult patients with previously treated metastatic microsatellite stable (MSS) colorectal cancer |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2017.357 | A Phase Ib/II, open label, multicenter study of MCS110 in combination with PDR001 in patients with advanced malignancies |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2017.404 | ElevatION: CRC-101: A Phase Ib study of PDR001 in combination with bevacizumab and mFOLFOX6 as first line therapy in patients with metastatic MSS colorectal cancer |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2016.443 | A PHASE III, OPEN LABEL, MULTICENTER, THREE-ARM, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF COBIMETINIB PLUS ATEZOLIZUMAB AND ATEZOLIZUMAB MONOTHERAPY VS. REGORAFENIB IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC COLORECTAL ADENOCARCINOMA |
Prof. MA Brigette Buig Yue 馬碧如 |
| 2015.455 | A phase II, open-label, randomized controlled study of PDR001 in patients with moderately differentiated/undifferentiated locally advanced recurrent or metastatic nasopharyngeal carcinoma who progressed on standard treatment |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2016.385 | A phase I/II, multicenter, open-label study of MAK683 in adult patients with advanced malignancies |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2015.442 | A Phase I/II, open label, multicenter study of the safety and efficacy of LAG525 single agent and in combination with PDR001 administered to patients with advanced malignancies |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2014.662 | A phase Ib dose-finding study of BYL719 plus everolimus and BYL719 plus everolimus plus exemestane in patients with advanced solid tumors, with dose-expansion cohorts in renal cell cancer (RCC), pancreatic neuroendocrine tumors (pNETs), and advanced breast cancer (BC) patients. | Prof. MA Brigette Buig Yue |
| 2014.357 | A PHASE Ib STUDY OF THE SAFETY AND PHARMACOLOGY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) ADMINISTERED WITH ERLOTINIB OR ALECTINIB IN PATIENTS WITH ADVANCED NON−SMALL CELL LUNG CANCER | Prof. MA Brigette Buig Yue |
| 2020.367 | A FIRST IN-HUMAN, PHASE 1/2 STUDY OF CFI-402411, HEMATOPOIETIC PROGENITOR KINASE-1 (HPK1) INHIBITOR, AS A SINGLE AGENT AND IN COMBINATION WITH PEMBROLIZUMAB IN SUBJECTS WITH ADVANCED SOLID MALIGNANCIES |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2020.591 | AN OPEN-LABEL, PHASE III STUDY OF PLATINUM-GEMCITABINE WITH OR WITHOUT NIVOLUMAB IN THE FIRST-LINE TREATMENT OF RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA |
Prof. MA Brigette Buig Yue 馬碧如 |
| 2019.684 | An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2020.457 | A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS TIRAGOLUMAB IN COMBINATION WITH PACLITAXEL AND CISPLATIN COMPARED WITH PACLITAXEL AND CISPLATIN AS FIRST-LINE TREATMENT IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED, UNRESECTABLE RECURRENT, OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA |
Prof. MA Brigette Buig Yue 馬碧如 教授 |
| 2019.342 | Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2018.436 | A Phase Ib, multicenter, open-label dose escalation and expansion platform study of select immunotherapy combinations in adult patients with triple negative breast cancer |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2020.168 | A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma |
Prof. MA Brigette Buig Yue 馬碧如 |
| 2019.002 | A phase I/Ib, open-label, multi-center, study of DKY709 as a single agent and in combination with PDR001 in patients with advanced solid tumors |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2019.327 | A Phase Ib, open-label, multi-center study to characterize the safety, tolerability, and preliminary efficacy of TNO155 in combination with spartalizumab or ribociclib in selected malignancies |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2024.063 | NRG-HN011: A RANDOMIZED PHASE II STUDY OF NIVOLUMAB VERSUS NIVOLUMAB AND BMS-986016 (RELATLIMAB) AS MAINTENANCE TREATMENT AFTER FIRST-LINE TREATMENT WITH PLATINUM-GEMCITABINE-NIVOLUMAB FOR PATIENTS WITH EPSTEIN-BARR VIRUS-ASSOCIATED RECURRENT/METASTATIC NASOPHARYNGEAL CARCINOMA (REMAIN) | Prof. MA Brigette Buig Yue |
| 2024.095 | A Phase 1b/2, Open-Label, Dose Escalation and Expansion Study of ADG126 in Combination with Pembrolizumab (Anti-PD-1 Antibody) in Patients with Advanced/Metastatic Solid Tumors | Prof. MA Brigette Buig Yue |
| 2022.413 | A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer |
Prof. MA Brigette Buig Yue 馬碧如 |
| 2021.630 | An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients with Advanced Epstein-Barr Virus- Positive (EBV+) Solid Tumors and in Combination with Pembrolizumab in Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma | Prof. MA Brigette Buig Yue |
| 2023.373 | A Phase I/II, Open-Label, Multi-Center Study of ALE.C04 (anti-Claudin-1 Antibody) as a Single Agent and in Combination with Pembrolizumab (anti-PD-1 antibody) in Adult Patients with Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma | Prof. MA Brigette Buig Yue |
| 2021.556 | A phase 2 trial of TAS 102 in recurrent/metastatic nasopharyngeal carcinoma |
Prof. MA Brigette Buig Yue 馬碧如 |
| 2023.455 | Multi-modal Deep Learning of Multiomics Profiles, Radiology and Histopathology Images to Advance Colorectal Cancer Classification for Precision Oncology |
Prof. MA Brigette Buig Yue 馬碧如 |
| 2022.408 | Clinical application of circulating tumour DNA (ctDNA) assay for monitoring treatment response in advanced gastrointestinal cancers (‘PROCURE-liquid’ program) | Prof. MA Brigette Buig Yue |
| 2017.540 | A phase I/II study of safety and efficacy of ribociclib (LEE011) in combination with trametinib (TMT212) in patients with metastatic or advanced solid tumors |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2019.153 | A Phase I/Ib, open-label, multi-center study of NZV930 as a single agent and in combination with PDR001 and/or NIR178 in patients with advanced malignancies |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2020.054 | A phase I/Ib, open-label, multi-center, study of KAZ954 as a single agent and in combination with Spartalizumab, NZV930 and NIR178 in patients with advanced solid tumors |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2010.251 | Uncontrolled, open-label, non-randomized, phase 1 study to investigate the pharmacokinetics, safety, tolerability, and efficacy of BAY 73-4506 in Chinese patients with advanced, refractory solid tumors | Associate Professor Ma Brigette Buig-Yue |
| 2010.473 | An East Asian phase I, multicenter, open-label, dose-escalation study of oral LDE225 in patients with advanced solid tumors | Associate Prof. Ma Buig Yue Brigette |
| 2010.466 | SAVOR Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus A Multicenter, Randomised, Double-Blind, Placebo-Controlled Phase IV Trial to Evaluate the Effect of Saxagliptin on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischaemic Stroke in Patients with Type 2 Diabetes | Professor Ma Ching Wan Ronald |
| 2012.052 | An evaluation on the effectiveness, acceptability and pricing of annual complication assessment for people with diabetes mellitus in the Hong Kong Community | Prof Ma Ching-wan, Ronald |
| 2017.282 | Mindfulness-based cognitive therapy for community-dwelling adults with anxiety symptoms: An exploration of efficacy and cognitive mechanism |
Miss MA Duan Yang 馬端陽 |
| 2012.321 | An opinion Survey among frail elderly patients and their carers regarding their opinion about self-financed community care services | Dr MA HON MING |
| 2023.153 | Mitochondrial disease related mortality - evaluation of a large international cohort | Dr. MA Kam Hung |
| 2013.407 | Pharmacokinetic study of once-daily formulation of Tacrolimus (Advagraf_) in Chinese kidney transplant patients | Dr Ma King Wing, Terry |
| 2022.043 | Effects of a structured Tai Chi program on improving physical activity level, exercise self-efficacy, and health outcomes among pregnant women: A randomised controlled trial |
Ms. MA Nan 马楠 |
| 2015.241 | A Transdiagnostic Anger Management Program for Adult Psychiatric Inpatient |
Ms. MA Olivia 馬婉婷 |
| 2015.458 | The effect of imagery and rumination on depression: a mediation and intervention study |
Ms. MA Olivia 馬婉婷 |
| 2016.328 | Epigenetic markers of type 2 diabetes and diabetic complications |
Prof. MA Ronald 馬青雲 |
| 2016.103 | Unraveling the link between maternal hyperglycaemia and childhood obesity: Genome-wide methylation analysis in a prospective cohort of untreated gestational diabetes |
Prof. MA Ronald 馬青雲 |
| 2015.473 | Identification of genetic loci for birthweight and cardiometabolic traits in childhood |
Prof. MA Ronald 馬青雲 |
| 2013.432 | Identification of epigenetic markers in offspring exposed to maternal hyperglycaemia | Prof. MA Ronald |
| 2015.316 | Maternal exposure to Perfluorooctane sulfonate (PFOS) and the risk of childhood obesity and metabolic abnormalities in the offspring- analysis of a longitudinal birth cohort |
Prof. MA Ronald 馬青雲 |
| 2015.040 | Progression of glucose intolerance, cardiometabolic risk factors and subclinical atherosclerosis in Chinese women with Polycystic Ovary Syndrome | Prof. MA Ronald |
| 2018.357 | Comprehensive evaluation and mechanism investigation of the PAX4 gene R192H variant on diabetes, diabetes-related traits and diabetic complications |
Prof. MA Ronald 馬青雲 |
Page 160 of 254.